Biotechnology · San Diego, California, United States
$11.92
-1.44% (-$0.17)2026-07-09
Smart-Money SignalNeutral · 47/100— Insiders are net sellers over 90 days (-$989K, 5 sales vs 1 buy)
Revenue$18.3M
Net Income-$73.3M
EPS$-0.83
Market Cap$1.1B
Price Performance
Historical data including institutional events
Company Profile
T
Troy Wilson
CEO & Executive Director
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
The companyâs first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
The company is headquartered in San Diego, California.
